https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-10-11 / Neuro Oncol 2022 Oct;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-10-11 / Neuro Oncol 2022 Oct;2022-10-11 00:00:002022-10-11 00:00:00Cellular Immunotherapy for Medulloblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-09-18 / Curr Oncol 2022 Sep;29(9):6700-6713
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-09-18 / Curr Oncol 2022 Sep;29(9):6700-67132022-09-18 00:00:002022-09-27 14:47:20Immunogenic Cell Death Role in Urothelial Cancer Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-09-12 / Front Mol Biosci 2022;9:754100
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-09-12 / Front Mol Biosci 2022;9:7541002022-09-12 00:00:002022-09-12 00:00:003-Dimensional coculture of breast cancer cell lines with adipose tissue-Derived stem cells reveals the efficiency of oncolytic Newcastle disease virus infection labeling technology
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-09-09 / Cancer Immunol Immunother 2023 Apr;72(4):827-840
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-09-09 / Cancer Immunol Immunother 2023 Apr;72(4):827-8402022-09-09 00:00:002024-11-12 09:18:52A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-09-08 / Cancers (Basel) 2022 Sep;14(18)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-09-08 / Cancers (Basel) 2022 Sep;14(18)2022-09-08 00:00:002022-09-08 00:00:00Dendritic-Cell-Vaccine-Based Immunotherapy for Hepatocellular Carcinoma: Clinical Trials and Recent Preclinical Studies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-09-07 / Hepatobiliary Pancreat Dis Int 2022 Oct;21(5):440-449
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-09-07 / Hepatobiliary Pancreat Dis Int 2022 Oct;21(5):440-4492022-09-07 00:00:002022-09-07 00:00:00Current and emerging immunotherapeutic approaches for biliary tract cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-09-06 / Molecules 2022 Sep;27(18)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-09-06 / Molecules 2022 Sep;27(18)2022-09-06 00:00:002022-09-06 00:00:00Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-08-24 / Pharmaceutics 2022 Aug;14(9)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-08-24 / Pharmaceutics 2022 Aug;14(9)2022-08-24 00:00:002022-08-24 00:00:00Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-08-21 / Cancers (Basel) 2022 Aug;14(16)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-08-21 / Cancers (Basel) 2022 Aug;14(16)2022-08-21 00:00:002022-08-21 00:00:00Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-08-10 / Immunol Invest 2022 Nov;51(8):2133-2158
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-08-10 / Immunol Invest 2022 Nov;51(8):2133-21582022-08-10 00:00:002022-08-10 00:00:00Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities
